EYPT · EyePoint, Inc.
$0.40
-5.51% last session
End-of-day data · close of 2026-10-23
Market cap
<$1M
Enterprise value
<$1M
Trailing P/E
—
Forward P/E
-0.2
Dividend yield
0.0%
Beta
1.68
Avg volume
8M
Employees
0K
Daily Change %
-5.51%
5 Days Change
-9.09%
10 Days Change
-86.71%
30 Days Change
-89.04%
60 Days Change
-92.02%
Month to Day Change
-87.62%
Year to Day Change
-97.81%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — EYPT
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-20
Latest call per bank · past 12 months
RBC Capital
Sector Perform$1.00
+150.0% vs priceJP Morgan
Underweight$0.00
-100.0% vs priceCitigroup
Buy$17.00
+4150.0% vs priceJefferies
Buy$8.00
+1900.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Laidlaw & Co. | Downgrade | Buy → Hold | $0.00 |
| 2026-10-20 | RBC Capital | Maintains | Sector Perform | $5.00 → $1.00 |
| 2026-10-20 | Guggenheim | Downgrade | Buy → Neutral | $0.00 |
| 2026-10-20 | JP Morgan | Downgrade | Neutral → Underweight | $0.00 |
| 2026-10-20 | HC Wainwright & Co. | Reiterates | Neutral | $0.00 |
| 2026-09-02 | TD Cowen | Downgrade | Buy → Hold | $20.00 → $4.00 |
| 2026-08-18 | Citigroup | Maintains | Buy | $35.00 → $17.00 |
| 2026-08-18 | RBC Capital | Downgrade | Outperform → Sector Perform | $37.00 → $5.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 15 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 89.8% below the 50-day MA ($3.91).
- bearish: Price vs 200-day MA: Trading 96.5% below the 200-day MA ($11.38).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.19) — short-term momentum is fading.
- bearish: 52-week range: Price is within 10% of the 52-week low ($0.40).
EYPT Price Chart
Loading chart for EYPT…
Fundamentals
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.